News

Children with cystic fibrosis (CF) used the Spiro PD device by themselves to measure their lung function and take their breathing medication at home, according to its maker, PMD Healthcare. Use of the device led to better lung function, the company reported. It published its study in Global Pediatric Health under the…

Doctors may soon diagnose cystic fibrosis (CF) with the help of a wristband, thanks to a new wearable sweat analysis tool that measures the molecular constituents of sweat, such as chloride ions and glucose. The device is an upgrade from earlier sweat analysis tools that required patients to be still for up to…

Running a full marathon isn’t a piece of cake for trained athletes, let alone people who struggle to breathe under normal circumstances. Yet two Spaniards with cystic fibrosis (CF) will be among the 40,000 people running in Madrid’s Rock ‘n’ Roll Marathon on Sunday, April 23. The annual 42-kilometer race, which…

The United States and Canada have given Laurent Pharmaceuticals a green light for a Phase 2 clinical trial of LAU-7b as a treatment for cystic fibrosis (CF) in adults. The Phase 2 door was opened when the U.S. Food and Drug Administration (FDA) and Health Canada approved the company’s investigational new drug (IND) application…

The first of a series of young-adult fantasy books from Michael Seidelman features a teenage girl with cystic fibrosis (CF). “No One Dies in the Garden of Syn,” whose main character is Synthia “Syn” Wade, explores topics that let young readers know more about the disease. Seidelman will donate…

Researchers at the University of Missouri School of Medicine have developed a helium-based imaging technique to measure how well Kalydeco, which fights mucus build-up in the lungs, is able to help cystic fibrosis (CF) patients. They discovered that it dramatically improved patients’ respiratory function. Helium imaging also can identify…

Arch Biopartners is on the verge of its first clinical trial of AB569, an inhalation treatment for antibiotic-resistant bacteria that infect the lungs of those with cystic fibrosis (CF) and other pulmonary conditions. The Phase 1 clinical trial, to be conducted at the Cincinnati Veterans Affairs Medical Center (CVAMC),…

Novoclem Therapeutics’ lead drug candidate, a nitric oxide-releasing biopolymer, can eliminate nine of the most prevalent microorganisms responsible for severe lung infections in cystic fibrosis (CF) patients, the Morrisville, N.C., company reported. “Our mission is to arm patients with therapies that treat resistant bacteria and enable them to breathe…

A small proof-of-concept Phase 2 trial (NCT02722122) of alidornase alfa showed that the therapy improved lung function in patients with cystic fibrosis (CF), according to its developer Protalix BioTherapeutics. In addition to making breathing difficult, the thick mucus in CF patients’ airways makes ideal growth conditions for many…

Swiss-based Polyphor has secured financing for late-stage development of Murepavadin (POL7080), an antibiotic targeting a bacteria that often infects the airways of cystic fibrosis (CF) patients. A hallmark of the therapy is that it goes after antibiotic-resistant strains of Pseudomonas aeruginosa, which infects not just MS patients, but people with other…